Offering a combination of genetic tests to people with a “very complex” blood cancer could accurately predict if the disease is likely to come back within 18 months of treatment, a study has found.
The method picks up “hidden risks” that traditional tests may miss, and could potentially benefit thousands of people in the UK with multiple myeloma, researchers said.
